Abstract
In 2015 the FDA approved an unprecedented number of new therapies for non-small cell lung cancer (NSCLC), among them therapies addressing specific genomic tumor subsets in the setting of development of resistance to front-line targeted therapy. Osimertinib (TagrissoTM, AZD9291) is indicated for patients with metastatic EGFR (epidermal growth factor receptor) T790M mutation-positive NSCLC, as detected by an FDA-approved test, who have progressed on or after EGFR tyrosine kinase inhibitor therapy and received breakthrough therapy designation, priority review status, and accelerated approval.

This publication has 23 references indexed in Scilit: